Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering therapies for serious and complex diseases, with a primary emphasis on neurology, specialized immunology, and rare diseases. The company markets a portfolio of medicines for multiple sclerosis, including VUMERITY, TYSABRI, TECFIDERA, AVONEX, and PLEGRIDY, as well as SPINRAZA for spinal muscular atrophy, SKYCLARYS for Fabry disease, and QALSODY for amyotrophic lateral sclerosis. Biogen co-develops and commercializes LEQEMBI for Alzheimer's disease with Eisai and ZURZUVAE for postpartum depression with Supernus. The company holds business and financial rights to a range of anti-CD20 therapies, including RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI, pursuant to collaboration arrangements with Genentech, a member of the Roche Group. Additionally, Biogen commercializes biosimilars such as BENEPALI, IMRALDI, and FLIXABI. The company serves markets in the United States, the European Union, and other international regions, and has expanded its pipeline through collaborations with partners such as Dayra Therapeutics, Vanqua Bio, City Therapeutics, and Stoke Therapeutics, as well as the acquisition of Alcyone Therapeutics.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage biogen.com
Sector Healthcare IR page biogen.com
Tags
neurology, rare diseases, specialized immunology, multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis, fabry disease, alzheimer's disease, biosimilars, anti-cd20 therapies, rnai therapies, antisense oligonucleotides, VUMERITY, TYSABRI, TECFIDERA, AVONEX, PLEGRIDY, SPINRAZA, SKYCLARYS, QALSODY, LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, COLUMVI, BENEPALI, IMRALDI, FLIXABI, Alcyone Therapeutics, ThecaFlex DRx, Dayra Therapeutics, Vanqua Bio, City Therapeutics, Stoke Therapeutics, zorevunersen, Eisai, Supernus, Genentech, Roche Group
Press page —

Metrics

Valuation  
Market cap $ 33.39B
Market cap (USD) $ 33.39B
P/E 97.36
PEG —
P/BV 1.76
P/S 3.24
P/OCF 14.86
P/FCF 16.12
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.4%
ROI 5.3%
ROIC 8.4%
Profit margin 13.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -24.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 38.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 70
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 9.891B 9.676B 9.836B 10.173B 10.982B 13.445B 14.378B 13.453B 12.274B 11.449B 10.764B 9.703B 6.932B 5.516B 5.049B 4.716B 4.377B 4.098B 3.172B 2.683B 2.423B 2.212B 679.183M — — —
Net profit 1.293B 1.632B 1.161B 3.047B 1.556B 4.001B 5.889B 4.431B 2.539B 3.703B 3.547B 2.935B 1.862B 1.38B 1.234B 1.005B 970.132M 783.167M 638.172M 217.511M 160.711M 25.086M -875.097M 148.09M 101.659M 48.145M
Free cash flow 2.051B 2.722B 1.27B 1.144B 3.382B 3.805B 6.564B 5.417B 3.684B 3.906B 3.073B 2.654B 2.099B 1.625B 1.52B 1.452B 909.252M 1.289B 736.529M 642.956M 571.127M 366.973M -82.035M 13.317M 86.434M 30.551M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 175.99 152.92 258.77 276.92 239.92 244.86 296.73 300.92 318.57 283.58 306.35 339.45 279.58 146.44 110.05 67.05 53.5 47.62 57.18 50.99 43.45 66.84 — — — —
Price performance 12m 0.15 -0.41 -0.07 0.15 -0.02 -0.17 -0.01 -0.06 0.12 -0.07 -0.1 0.21 0.91 0.33 0.64 0.25 0.12 -0.17 0.12 0.17 -0.35 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.44B 1.79B 1.96B 1.88B 1.91B 1.55B 1.71B 1.66B 1.4B 1.34B
↳ YoY growth +17.5% +24.0% +9.6% -4.0% +1.8% -19.0% +10.0% -2.4% -15.6% -4.4%
↳ 5y CAGR +19.8% +21.1% +18.9% +7.8% +9.3% +1.5% -0.9% -3.2% -5.7% -6.8%
Borrowings, current (USD) 4.7M 3.2M 0.00 1.5B 0.00 999M 0.00 150M 1.75B 0.00
Borrowings, non-current (USD) 16.4M 0.00 — — — — — — — —
Lease liabilities (USD) — — 0.00 413M 402M 330M 430M 490M 421M 371M
Cash and deposits (USD) 2.33B 1.57B 1.22B 2.91B 1.33B 2.26B 3.42B 1.05B 2.38B 3.01B
Intangible assets (USD) 3.81B 3.88B 3.12B 3.53B 3.08B 2.22B 1.85B 8.36B 9.69B 9.18B
Right-of-use assets (USD) — — 0.00 427M 433M 375M 404M 420M 356M 265M
Net debt (borrowings + leases - cash) (USD) -2.31B -1.57B -1.22B -1.01B -929M -932M -2.99B -410M -206M -2.64B
Cash flow detail
Operating cash flow (USD) 4.52B 4.55B 6.19B 7.08B 4.23B 3.64B 1.38B 1.55B 2.88B 2.2B
Purchases of property, plant and equipment (USD) -616M -867M -771M -515M -425M -258M -240M -277M -154M -154M
Purchases of intangible assets (USD) -112M -975M -3M -155M -52M -18.8M -2.9M -34.4M -206M -31.6M
Change in receivables (cash effect) (USD) -241M -436M -205M 68.8M 2.8M 325M -203M 61.3M 222M 103M
Change in inventories (cash effect) (USD) -166M -94.5M -52.1M -19.2M -316M -462M -320M -131M -274M -64.7M
Share buybacks (cash effect) (USD) -1B -1.37B -4.35B -5.87B -6.68B -1.8B -750M 0.00 0.00 —
Interest paid (cash effect) (USD) -281M -282M -243M -244M -273M -281M -263M -252M -245M -264M
Income taxes paid (cash effect) (USD) -1.64B -1.07B -1.01B -1.06B -907M -248M -933M -741M -355M -864M
Share-based compensation (USD) 155M 128M 158M 182M 198M 239M 254M 264M 291M 291M
Operating cash flow before change in receivables (USD) 4.76B 4.99B 6.39B 7.01B 4.23B 3.32B 1.59B 1.49B 2.65B 2.1B
Free cash flow (OCF - PPE - intangibles) (USD) 3.79B 2.71B 5.41B 6.41B 3.75B 3.36B 1.14B 1.24B 2.52B 2.02B
Income detail
Research and development expense (USD) 1.97B 2.25B 2.6B 2.28B 3.99B 2.5B 2.23B 2.46B 2.04B 1.78B
↳ 5y CAGR +10.1% +11.0% +12.5% +3.8% +14.7% +4.9% -0.2% -1.1% -2.2% -14.9%
Total comprehensive income (USD) 3.6B 2.67B 4.55B 5.99B 3.9B 1.92B 2.9B 1.17B 1.65B 1.25B
Comprehensive income to owners (USD) 3.61B 2.54B 4.51B 5.99B 3.84B 1.75B 2.99B 1.17B 1.65B 1.25B
Reported Feb 2, 2017 Feb 1, 2018 Apr 24, 2019 Feb 6, 2020 Feb 3, 2021 Feb 3, 2022 Feb 15, 2023 Feb 14, 2024 Feb 12, 2025 Feb 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 29, 2026

PDF Version

  • Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease

  • Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration

  • Presentations across Biogen’s Alzheimer’s disease portfolio reflect its continued commitment to advancing innovation in Alzheimer’s disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts. Presentations will include expanded data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of lecanemab (brand name: LEQEMBI®).

"Biogen has a long-standing commitment to advancing innovation in Alzheimer's disease, from generating evidence that informs clinical practice to pursuing novel approaches that target core disease pathologies," said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. “At CTAD, we look forward to sharing important updates across our portfolio, including additional long-term and real-world evidence for LEQEMBI and new data from the Phase 2 CELIA study evaluating diranersen.”

Featured Scientific Sessions and Presentations

Diranersen Diranersen is an investigational ASO designed to target MAPT mRNA and reduce the production of all tau isoforms, lowering both intracellular and extracellular tau protein. At CTAD, Biogen will present clinical, biomarker and safety data that build on results previously reported in July 2026 and further characterize the clinical, biomarker and safety profile of diranersen in the Phase 2 CELIA study in early Alzheimer's disease.

  • **Late Breaking Symposium: Additional Biomarker and Clinical Findings from the Phase 2 CELIA Study of Diranersen in Early Alzheimer’s Disease:**Late Breaking Symposium 1, Tuesday, November 17, 4:45–5:25 PM EST This symposium will feature three analyses from CELIA, including 96-week long-term extension efficacy and safety data, additional 76-week tau biomarker and amyloid PET data, and 76-week item analyses and select subgroup efficacy data. These data build on previously reported CELIA results and further characterize the clinical, biomarker and safety profile of diranersen in early Alzheimer's disease.

Lecanemab Featured lecanemab sessions at CTAD will highlight continued real-world evidence generation and long-term outcomes data related to the treatment of early Alzheimer’s disease.

  • Symposium 5: Featured Research Session: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse U.S. Clinical Settings Wednesday, November 18, 11:00–11:40 AM EST This session will feature new real-world evidence from the LEADER study, including findings on lecanemab utilization and outcomes from treatment initiation through maintenance therapy, sex-based outcomes, and experience with at-home subcutaneous lecanemab administration across diverse U.S. clinical settings.

  • Oral Communication: Long-Term Outcomes with Lecanemab in Early Alzheimer’s Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension Monday, November 16, 6:00 PM EST This oral presentation will report initial findings through five years of the Clarity AD open-label extension, including long-term clinical outcomes, disease progression and safety with continued lecanemab treatment in early Alzheimer's disease.

Selected Additional Oral and Poster Presentations Additional oral and poster presentations at CTAD highlight Biogen’s ongoing efforts to advance Alzheimer’s disease diagnosis, treatment and care, including real-world experience with lecanemab, approaches to patient identification and testing, treatment outcomes, and analyses modeling the potential broader impact of slowing disease progression. For a complete list of presentations, please refer to the CTAD scientific program.

  • Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice Tuesday, November 17, 2:05–2:20 PM EST

  • Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy Thursday, November 19, 1:35–1:50 PM EST

  • US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) Poster Session

  • Baseline Radiologic Predictors of ARIA-E and ARIA-H: A Quantitative AI-Supported MRI Analysis of a US Real-World Cohort Poster Session

  • A Prospective, Observational, Fully Decentralized Global Study to Identify Individuals for Alzheimer’s Disease Clinical Trials Using Digital Cognitive Assessments and Blood-Based Biomarkers Poster Session

About diranersen (BIIB080) Diranersen (BIIB080) is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease associated with neurodegeneration and cognitive decline.

Diranersen is being investigated as a potential treatment for early Alzheimer’s disease. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease. In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was discovered by Ionis.

About the CELIA Study CELIA is a global Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. All participants enrolled in CELIA had not previously received anti-amyloid therapy.

The study evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months, and 115 mg every three months.

The primary endpoint of CELIA was assessment of dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory endpoints included additional clinical, biomarker and imaging measures, including cerebrospinal fluid tau biomarkers and tau positron emission tomography (PET). Additional information on the CELIA study design is available in the ClinicalTrials.gov listing for the CELIA study.

An ongoing long-term extension (LTE) study is continuing to evaluate the long-term safety, tolerability and durability of diranersen in early Alzheimer’s disease.

About lecanemab (brand name: LEQEMBI**®)** Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 9 countries including the U.S., China, the UK, and others, and applications have been filed in 11 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing (360 mg) with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the U.S. in July 2026 and China in September 2026, and applications are under review in 2 countries.

Eisai and Biogen have been collaborating on the joint development and commercialization of Alzheimer’s disease treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor This news release contains forward-looking statements, including, among others, relating to: the potential benefits, efficacy and safety of diranersen (BIIB080) and lecanemab (LEQEMBI); the potential to advance care and improve outcomes for, and address unmet needs of, patients with Alzheimer’s disease; potential regulatory discussions, submissions, decisions and approvals and the timing thereof; the anticipated benefits, risks and potential of our collaboration arrangements; the potential of our commercial business and pipeline programs, including Biogen’s research programs for Alzheimer’s disease; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.

| MEDIA CONTACT: Madeleine Shin + 1 781 464 3260 [email protected] | INVESTOR CONTACT: Tim Power +1 781 464 2442 [email protected] |

Biogen Reports Third Quarter 2026 Results Bull 5 Bear 0 Results

October 19, 2026

  • Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profile

  • Additional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)

  • Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.

Key presentations include new EMPAVELI data showing sustained proteinuria reduction and continued estimated glomerular filtration rate (eGFR) stabilization in patients with C3G and primary IC-MPGN over 76 weeks. This data follows the recent U.S. Food and Drug Administration update to expand EMPAVELI’s indication to include reducing the loss of kidney function, making it the first and only therapy approved to reduce both proteinuria and the loss of kidney function in adults and adolescents aged 12 years and older with C3G and primary IC-MPGN. Additional presentations on pegcetacoplan and felzartamab will provide insights into the management and understanding of multiple immune-mediated kidney diseases.

“Data shared this week further reinforce EMPAVELI’s long-term efficacy and safety profile, while new scientific insights highlight the significant unmet needs and lack of proven therapies in AMR, supporting the potential of felzartamab to address critical gaps in transplant care and other kidney diseases,” said Daniel Quirk, MD, Chief Medical Officer at Biogen. “Biogen’s current research now spans seven different kidney diseases, and we’re proud to share updates on our portfolio’s progress with the nephrology community at this premier scientific congress.”

Biogen will also be hosting two exhibitor spotlights and 9 poster presentations related to both EMPAVELI and felzartamab. Felzartamab is currently being studied in three Phase 3 trials, TRANSCEND (NCT06685757) for AMR in adult kidney transplant recipients, PREVAIL (NCT06935357) in IgA nephropathy, and PROMINENT (NCT06962800) in primary membranous nephropathy, and a Phase 2 trial in microvascular inflammation (NCT07219043). Data from the TRANSCEND study is expected in H1 2027.

Prompts

Biogen Inc. (ticker BIIB), listed in United States.

Company History

Date Change Detail
Aug 8, 2023 Acquired Acquired Reata Pharmaceuticals Inc (CIK 1358762). Its filings from before the deal are on its own company page, not shown here.
Mar 23, 2015 Renamed BIOGEN IDEC INC. → BIOGEN INC.
Nov 12, 2003 Renamed IDEC PHARMACEUTICALS CORP / DE → BIOGEN IDEC INC
— Predecessor Predecessor Biogen Inc (CIK 714655) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Biogen Inc.

ETF Weight in ETF Shares Market value As of
FMKT 4.69% 1,834 $ 461.526K Nov 17, 2026
BMED 3.78% 2,150 $ 541.048K Nov 16, 2026
STNC 3.11% 14,218 $ 2.886M Jul 31, 2026
MEDX 3.09% 2,726 $ 588.98K Jun 30, 2026
SPIT 2.36% 3,695 $ 800.522K Aug 31, 2026
FRTY 2.33% 16,594 $ 3.585M Jun 30, 2026
SAMM 2.20% 3,090 $ 667.625K Jun 30, 2026
SAGP 2.08% 7,383 $ 1.595M Jun 30, 2026
JDOC 1.68% 663 $ 166.274K Nov 17, 2026
TMED 1.55% 1,654 $ 357.363K Jun 30, 2026
CVAR 1.36% 2,887 $ 585.917K Jul 31, 2026
CGV 1.16% 7,382 $ 1.498M Jul 31, 2026
ABCS 0.75% 431 $ 93.376K Aug 31, 2026
ITAN 0.75% 3,687 $ 924.663K Nov 17, 2026
FBCV 0.71% 6,217 $ 1.262M Jul 31, 2026
LSVD 0.58% 18,519 $ 3.758M Jul 31, 2026
CLSE 0.53% 22,150 $ 4.799M Aug 31, 2026
RCGE 0.53% 2,093 $ 520K Nov 18, 2026
AVMC 0.42% 9,279 $ 2.335M Nov 16, 2026
JAVA 0.37% 111,420 $ 27.943M Nov 17, 2026
FEMV 0.34% 84 $ 18.149K Jun 30, 2026
FLCV 0.29% 1,874 $ 406.002K Aug 31, 2026
AVIE 0.29% 193 $ 48.568K Nov 16, 2026
VFMF 0.25% 11,328 $ 2.454M Aug 31, 2026
AFLG 0.25% 9,335 $ 2.349M Nov 16, 2026
FFLC 0.24% 14,244 $ 2.891M Jul 31, 2026
REMC 0.22% 35 $ 7,562.10 Jun 30, 2026
VFVA 0.22% 9,741 $ 2.11M Aug 31, 2026
SGLC 0.21% 2,086 $ 451.932K Aug 31, 2026
JSTC 0.20% 2,375 $ 597.669K Nov 17, 2026
MODL 0.19% 9,148 $ 1.977M Jun 30, 2026
THRO 0.19% 76,851 $ 19.34M Nov 16, 2026
FLSP 0.17% 7,627 $ 1.648M Jun 30, 2026
FTLS 0.16% 16,089 $ 0.00 Nov 16, 2026
CAPE 0.15% 1,601 $ 345.912K Jun 30, 2026
NBCR 0.14% 5,318 $ 1.152M Aug 31, 2026
VFMO 0.13% 11,801 $ 2.557M Aug 31, 2026
HBTA 0.12% 1,425 $ 308.726K Aug 31, 2026
IQSZ 0.12% 1,048 $ 212.692K Jul 31, 2026
DFUV 0.11% 69,322 $ 17.364M Nov 12, 2026
BRCE 0.10% 177 $ 38.347K Aug 31, 2026
BDVL 0.10% 6,849 $ 1.724M Nov 16, 2026
AVSU 0.10% 1,994 $ 501.79K Nov 16, 2026
AAUS 0.10% 2,101 $ 530K Nov 18, 2026
DFLV 0.10% 29,512 $ 7.392M Nov 12, 2026
AVUS 0.09% 49,134 $ 12.365M Nov 16, 2026
AVLC 0.09% 5,772 $ 1.453M Nov 16, 2026
XMAG 0.08% 724 $ 181.348K Nov 13, 2026
DFSU 0.08% 7,521 $ 1.884M Nov 12, 2026
APUE 0.07% 8,494 $ 1.84M Aug 31, 2026
EBI 0.07% 2,214 $ 479.663K Aug 31, 2026
FELV 0.07% 10,172 $ 2.198M Jun 30, 2026
VSLU 0.07% 1,720 $ 371.623K Jun 30, 2026
INRO 0.06% 1,370 $ 344.761K Nov 16, 2026
DFAU 0.06% 30,572 $ 7.658M Nov 12, 2026
TCAF 0.06% 24,493 $ 6.164M Nov 17, 2026
DFUS 0.05% 45,465 $ 11.388M Nov 12, 2026
TACU 0.05% 36 $ 9,059.40 Nov 17, 2026
DFAC 0.05% 172,095 $ 43.106M Nov 12, 2026
DXUV 0.05% 12,163 $ 3.047M Nov 12, 2026
NTSD 0.05% 79 $ 17.069K Jun 30, 2026
FLCC 0.05% 277 $ 60.012K Aug 31, 2026
VOXP 0.04% 12 $ 2,435.40 Jul 31, 2026
DCOR 0.04% 72,753 $ 18.223M Nov 12, 2026
DYNF 0.04% 61,542 $ 15.487M Nov 16, 2026
LGDX 0.04% 221 $ 55.615K Nov 17, 2026
GDE 0.04% 880 $ 190.652K Aug 31, 2026
HCMT 0.04% 1,026 $ 208.227K Jul 31, 2026
NTSX 0.03% 1,589 $ 343.319K Jun 30, 2026
CSHP 0.02% 255 $ 64.171K Nov 16, 2026
GSPY 0.02% 472 $ 118.779K Nov 17, 2026
ACVF 0.02% 134 $ 27.195K Jul 31, 2026
FMDE 0.00% 9 $ 1,944.54 Jun 30, 2026
IALT short 0.00% -1,180 $ -296.947K Nov 16, 2026
CORO 0.00% 93 $ 23.45K Nov 16, 2026